Growth Metrics

Guardant Health (GH) EBIT Margin (2017 - 2025)

Guardant Health's EBIT Margin history spans 9 years, with the latest figure at 42.95% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 1947.0% year-over-year to 42.95%; the TTM value through Dec 2025 reached 44.53%, up 1550.0%, while the annual FY2025 figure was 44.53%, 1550.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 42.95% at Guardant Health, down from 37.33% in the prior quarter.
  • Across five years, EBIT Margin topped out at 37.33% in Q3 2025 and bottomed at 137.12% in Q1 2021.
  • The 5-year median for EBIT Margin is 89.03% (2021), against an average of 87.58%.
  • The largest annual shift saw EBIT Margin plummeted -8540bps in 2021 before it skyrocketed 6497bps in 2024.
  • A 5-year view of EBIT Margin shows it stood at 90.84% in 2021, then decreased by -27bps to 115.15% in 2022, then decreased by -11bps to 127.38% in 2023, then soared by 51bps to 62.42% in 2024, then surged by 31bps to 42.95% in 2025.
  • Per Business Quant, the three most recent readings for GH's EBIT Margin are 42.95% (Q4 2025), 37.33% (Q3 2025), and 45.85% (Q2 2025).